HORMONSKO NADOMJESNO LIJEČENJE CLIMENOM© I NJEGOV UČINAK NA TKIVO DOJKE

Objective. To evaluate the effect of the hormone replacement therapy on breast changes in postmenopausal women. Material and methods. The study includes 35 women with natural or surgical menopause who were treated with sequential estrogen/progestogen hormone replacement therapy (E/P HRT) during one year. The therapeutic program consisted of three weeks treatment with estradiol valerate 2 mg/day orally, combined with ciproterone acetate 1 mg/day in the last 10 days (Climen© – Schering) followed by one week pause. Before the start with E/P HRT basic mammography and ultrasound examination of the breast tissue was performed in all patients. At the end of the study after 12 therapeutic cycles, control mammography and ultrasonographic examination were done. Results. In the short-term study 18 patients (51.43%) showed regression of the finding, 15 (42.86%) stagnation, and only 2 (5.71%) progression of the finding (D=0.27, p<0.01). Conclusion. A clear consensus regarding the relationship between HRT and breast cancer risk cannot yet be drawn.Cilj rada je bio vrednovati učinak hormonskog nadomjesnog liječenja na promjene dojke u 35 žena u post¬menopauzi. Bolesnice i način istraživanja. 35 žena u prirodnoj ili kirurškoj postmenopauzi je kroz jednu godinu liječeno sekvencijskom hormonskom nadomjesnom terapijom (HNL). Terapijska shema je bila tri tjedna estradiol valerijanat 2 mg/dan peroralno, kombinirano s ciproteron acetatom 1 mg/dan posljednjih 10 dana (Climen© – Schering) te nakon toga sedam dana stanke. Prije početka HNL svima je pacijenticama učinjena mamografija i ultrazvučni pregled dojki. Na kraju studije, nakon 12 terapijskih ciklusa, učinjeni su kontrolna mamografija i pregled ultrazvukom. Rezultati. U kratkoročnoj studiji u 18 pacijentica (51,43%) nastupila je regresija nalaza, u 15 (42,86%) stagnacija i u 2 (5,71%) pacijentice progresija nalaza (D=0,27, p